Summary
The provided audit content is largely consistent with the cited FDA label sections for contraindication, thyroid C-cell tumor risk, and patient counseling. However, it does not evaluate boxed warning text specifically, and it does not assess other label areas typically required for a comprehensive label-alignment check (e.g., dosage/administration, monitoring detail for calcitonin/ultrasound decision-making, adverse reactions beyond a reference).
Category Scores
Accurate Statements
OZEMPIC is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2.
4 CONTRAINDICATIONS
In mice and rats, semaglutide caused a dose-dependent and treatment-duration-dependent increase in thyroid C-cell tumors, and it is unknown whether OZEMPIC causes thyroid C-cell tumors, including MTC, in humans.
5.1 Risk of Thyroid C-Cell Tumors
Patients should be informed about the potential risk for MTC/thyroid C-cell tumors and symptoms (e.g., mass in neck/lump, hoarseness, dysphagia, dyspnea).
5.1 Risk of Thyroid C-Cell Tumors and 17 PATIENT COUNSELING INFORMATION
Unsupported Statements
Contradictions
Important Omissions
Boxed warning content itself was not provided/evaluated directly (only referenced).
Importance:
Moderate
Warning section 5.1 includes specific statements about routine monitoring of serum calcitonin and thyroid ultrasound being of uncertain value/possible unnecessary procedures, and about further evaluation when calcitonin is elevated or nodules are present; these details were not explicitly assessed in the audit output.
Importance:
Moderate
Adverse reaction coverage in the provided label excerpt is limited to a reference to serious adverse reactions (Risk of Thyroid C-cell tumors). The audit does not assess alignment for other adverse reactions (not provided) nor confirm that only the cited serious adverse reaction reference is consistent.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
No contradictions to contraindication or thyroid C-cell tumor risk were identified within the provided cited label sections. Primary gaps relate to not explicitly validating all specific warning/boxed-warning details included in section 5.1 and limited evaluation of adverse reaction content.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Incomplete verification of all specific Warnings/Precautions (5.1) elements and lack of direct boxed warning text evaluation.
Suggested Improvement
Explicitly map the audit output to every key element in 5.1 provided (including uncertainty/value of calcitonin/ultrasound monitoring and subsequent evaluation steps) and, if available, evaluate the boxed warning text itself rather than only references.